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Gastrointestinal disorders (especially diarrhea) are ob-
served in a proportion of patients treated with the cur-
rently approved combination treatment for chronic hepatitis
C (CHC), pegylated-interferon alpha (PEG-IFNa) plus rib-
avirin (RIB) [1]. Several reports suggest that the presence
of inﬂammatory bowel disease (IBD) is not a contraindica-
tion for interferon-alpha- (IFNa-) based treatments [2, 3].
Furthermore, a randomised placebo-controlled trial of PEG-
IFNa in patients with active ulcerative colitis concluded that
PEG-IFNa is safe but not eﬀective treatment for these pa-
tients [4]. On the contrary, several reports [5–8] revealed
that treatment of chronic viral hepatitis with IFNa or PEG-
IFNa with or without RIB was related with the onset of clin-
ically and histologically conﬁrmed acute colitis of the IBD
type. To our knowledge the eﬀect of chronic hepatitis C virus
(HCV) infection or PEG-IFNa plus RIB combination treat-
ment on large intestine histopathology has not been investi-
gated, within a clinical trial. The principal aim of our study
was to investigate the eﬀect of PEG-IFNa plus RIB treatment
on the large intestine histology of treated CHC patients.
Twenty-four treatment-na¨ ıve CHC patients with sero-
logically (antiHCV-positive, Abbott Laboratories, Abbott
Park, Ill, USA), virologically (serum HCV-RNA detection,
Cobas Amplicor HCV test, version 2, Roche Diagnostics,
Branchburg, NJ, USA), and histologically (liver biopsy-Ishak
scoring system) conﬁrmed CHC and no contraindication
of receiving combination treatment with PEG-IFNα2b and
RIB were enrolled in this pilot study. All patients were
treated with weight-based dosing of pegylated interferon-
a2b (Peg-Intron, 1.5μg/kg/week) and genotype-related rib-
avirin dose (Rebetol, 800mg/day for genotype 2/3 and 1000–
1200mg/day for genotype 1/4-infected patients, depending
on baseline body weight < or ≥85kg, resp.) for 24 weeks.
Patients were evaluated for the presence of gastrointesti-
nal symptoms, by receiving a detailed history, before the
beginning of treatment, during the treatment period and
at week 24 of treatment. The study population underwent
recto-sigmoidoscopic examination prior to the beginning of
the treatment schedule. Three to ﬁve biopsy specimens were
taken from the rectosigmoid area.
Histological ﬁndings characteristic of inﬂammation as
well as the presence of architectural disorders and the quan-
tity of mucus production, the presence of ulcerations and
Paneth cells as well as the numbers of lymphoid follicles in
every biopsy specimen were evaluated. Fifteen patients un-
derwent the same procedure after the completion of 24-week
treatment course and three of them were also evaluated dur-
ing treatment because of diarrhea. Ten age-, sex-, and BMI-
matched healthy subjects (control group) underwent recto-
sigmoidoscopic examination and biopsy. All controls had no
history of inﬂammatory bowel disease or other gastrointesti-
nal diseases, did not receive any medication and did not re-
port symptoms from the gastrointestinal tract. Written in-
formed consent was obtained from each participant for his
or her participation in the study. The study conformed to the
ethical guidelines of the 1975 Declaration of Helsinki.
No pathological macroscopic (endoscopic) ﬁndings were
identiﬁedatbaselineaswellasinendoscopicre-evaluationin
either patients or controls. CHC patients had no statistically
signiﬁcant diﬀerence in the presence of bowel inﬂammatory2 Gastroenterology Research and Practice
Table 1: Comparison of epidemiological and large intestine histopathology data between untreated CHC patients and controls.
CHC patients n = 24 Controls n = 10 P value
Gender (male/female) 14/10 6/4 1
Age (years) 37.04 ±14.02 46.00 ±13.38 .098
BMI (kg/m2)2 3 .09 ±3.31 23.26 ±3.78 .903
Inﬂammation (%) 14/24 (58.3%) 6/10 (60%) 1
Architectural disorder and decrease of mucus production (%) 6/24 (25%) 0/10 (0%) .148
Paneth cells (%) 4/24 (16.7%) 0/10 (0%) .296
Lymphoid follicles 1.33 ±1.50 1.60 ±1.43 .440
Table 2: Comparison of large intestine histopathology and diarrhea data of CHC patients before and after 24 weeks of treatment.
CHC patients before
treatment n = 15
CHCpatientsafter24
weeks of treatment n = 15
P value
Inﬂammation (%) 10/15 (66.7%) 8/15 (53.3%) .71
Architectural disorder and decrease of
mucus production (%) 6/15 (40%) 4/15 (26.7%) .70
Paneth cells 4/15 (26.7%) 0/15 .10
Lymphoid follicles 1.33 ±1.54 1.73 ±1.62 .97
Diarrhea (%) 0/15 3/15 (20%) .22
(a)
(b)
Figure 1: Histopathological evaluation of the large intestine at
baseline (a) and at the onset of symptoms (b) revealed normal large
intestine histology and mild chronic nonspeciﬁc colitis in the ﬁrst
patient with diarrhea, respectively.
inﬁltration compared to controls as shown in Table 1.I ti s
important to note that a respectable proportion of CHC pa-
tients exhibited architectural disorder and decreased mucus
production(25%)aswellaspresenceofP anethcells(16.7%),
compared to controls, but this does not reach statistical sig-
niﬁcance possibly due to the small sample size of the study
population. This ﬁnding needs further investigation because
of the documental lymphotropism of HCV and the well-
known HCV-related autoimmune manifestations.
No patient reported diarrhea before the initiation of
treatment whereas 3 patients reported diarrhea during the
treatment course. In particular, the ﬁrst patient reported di-
arrheaatweek6oftreatment,thesecondoneatweek12,and
the third one at week 14. Baseline histology was normal in all
three patients. Histopathological evaluation of the large in-
testine at the onset of symptoms revealed mild chronic non-
speciﬁc colitis in the ﬁrst patient (Figure 1) and normal large
intestinehistologyintheothertwopatients,respectively.The
same ﬁndings were repeated in these patients in the histolog-
ical re-evaluation at week 24 of treatment. Diarrhea sponta-
neously resolved in all of them within 5–7 days and none of
them followed treatment discontinuation.
There was no statistically signiﬁcant diﬀerence between
the percentage of patients with large intestine inﬂammation
before the initiation and at week 24 of treatment (66.7% ver-
sus 53.3% resp., P = .71). Particularly, 6/15 patients exhibited
mild inﬂammatory inﬁltration before the initiation as well as
at week 24 and 3/15 exhibited absence of inﬂammation both
before and at week 24 of treatment. Moreover, 4/15 positive
patients for the presence of inﬂammation before treatment
had normal large intestine histology at week 24 and ﬁnally,
2/15 patients had no ﬁndings of inﬂammation before treat-
ment but exhibited mild nonspeciﬁc inﬂammatory lesions at
week24.Nostatisticallysigniﬁcantdiﬀerenceswereobserved
before the beginning and at week 24 of combination treat-
ment regarding architectural disorder and decrease of mu-
cus production (P = .70), presence of Paneth cells (P = .10),
and the number of lymphoid follicles in every biopsy spec-
imen (P = .97) as shown in Table 2. Interestingly none of 4
patients with detectable Paneth cell at baseline evaluation ex-
hibitspresenceofthematweek24.ThisﬁndingneedsfurtherKonstantinos D. Pantazis et al. 3
investigation in large-scale studies because of the proposed
importance of these multifaceted cells in the pathophysiol-
ogy of IBD [9].
In conclusion, according to the preliminary results of our
pilot study, it seems that the immunomodulatory-antiviral
treatment of CHC with PEG-IFNa2b plus ribavirin for 24
weeks possibly does not signiﬁcantly aﬀect the large intes-
tine histology of treated patients, despite the appearance of
symptoms from the gastrointestinal tract in a subgroup of
them. The eﬀect of chronic HCV infection in the intestine
histopathology needs further investigation.
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